Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Media Mention

Terry Mahn Quoted in Law360’s “High Court Biosimilar Drama Intact After Amgen-Apotex Denial”

December 13, 2016

Media Mention

Terry Mahn Quoted in Law360’s “High Court Biosimilar Drama Intact After Amgen-Apotex Denial”

December 13, 2016

Back to News Listing

Article posted on Law360, December 12, 2016

The U.S. Supreme Court’s refusal Monday to review a major biosimilar ruling involving Amgen and Apotex doesn’t necessarily mean that justices agree with the ruling, according to attorneys who predict that justices may use a separate case to tackle the same question about notice of biosimilar sales.

“Having dismissed the Amgen v. Apotex petition leaves the law as it is but doesn’t necessarily mean the court isn’t going to decide it,” Fish & Richardson P.C. principal Terry G. Mahn said. “This could be a total nonevent.”

 

To read the full article, click here.


The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.